


Appln No.: 10/595,845
Amendment Dated: February 12, 2008
Reply to Office Action of January 30, 2008

REMARKS/ARGUMENTS

This is in response to the Office Action mailed January 30, 2008 for the above-captioned application. Applicants hereby elect the invention of claims 5, 9, 15, 17 and 19, defined as Group I by the Examiner. As noted by the Examiner, claims 1-4, 7 and 8 are generic linking claims.

Attached to the Office Action was notice of non-compliant amendment stating that the previous amendment was non-compliant because claims 1 and 7 were indicated as original rather than showing an amendment to add the language "wherein the therapeutic agent targets $\beta 4$." Applicants respectfully disagree with this statement. The amendment to the claim was made during prosecution of the PCT application, via an Amendment Under PCT Article 19, and was not made in the preliminary amendment. This was noted in the comments accompanying the preliminary amendment. This amendment during the PCT phase is part of the prosecution of this application. However, in an effort to be responsive to the Examiner's remarks, the amendment is presented again here, with the status identifier of previously presented in for claims 1 and 7.

Respectfully submitted,



Marina T. Larson, Ph.D
Attorney/Agent for Applicant(s)
Reg. No. 32038

(970) 262-1800